Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Medpace Holdings, Inc. (Nasdaq: MEDP), a scientifically driven, global, full-service clinical contract research organization (CRO). Through these filings, investors can review the company’s official financial statements, risk disclosures, material agreements and other regulatory information that frame analysis of MEDP stock.
Medpace’s SEC reporting includes annual reports on Form 10-K, which contain audited financial statements, management’s discussion and analysis, and a detailed “Risk Factors” section describing uncertainties such as contract loss, backlog conversion, pricing pressure, international operations, regulatory compliance, and information systems risks. Quarterly reports on Form 10-Q provide interim financial updates and additional context on operating performance in the clinical research and development services business.
The company also files current reports on Form 8-K to disclose specific events. For example, Medpace has used Form 8-K to furnish earnings press releases under Item 2.02 and to describe amendments to its unsecured credit facility under Item 1.01, including changes to the aggregate principal amount available under its line of credit. These filings give detail on financing arrangements and other material developments beyond the headline numbers in press releases.
On Stock Titan, Medpace filings are paired with AI-powered summaries that highlight key points from lengthy documents, such as major changes in revenue and profitability, updates to guidance, or notable shifts in risk disclosures. Users can quickly scan 10-K and 10-Q reports, as well as 8-K items, while retaining the option to open the full SEC documents for deeper review. This page also surfaces information relevant to tracking management decisions, capital structure, and other regulatory matters that influence Medpace’s long-term profile as a global CRO.
Medpace Holdings, Inc. reported strong first quarter 2026 results with revenue of $706.6 million, up 26.5% from $558.6 million a year earlier. GAAP net income was $123.9 million, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, as net income margin moved from 20.5% to 17.5%.
EBITDA increased 25.9% to $149.4 million with a 21.1% margin, while backlog rose 2.9% to $2,929.2 million and net new business awards were $618.4 million, yielding a 0.88x net book-to-bill ratio. Cash and cash equivalents reached $652.7 million. For full year 2026, Medpace forecasts revenue of $2.755–$2.855 billion, GAAP net income of $487.0–$511.0 million, EBITDA of $605.0–$635.0 million, and diluted EPS of $16.68–$17.50. The company also announced that President Jesse Geiger will retire effective May 31, 2026, with CEO August Troendle reassuming the President role until a successor is appointed.
Medpace Holdings director Cornelius P. McCarthy III exercised restricted stock units that converted into 29 shares of common stock on March 31, 2026. The award was part of a 113-unit grant from November 28, 2025 that vests in four approximately equal installments through December 31, 2026. Following this vesting event, he directly owns 10,324 shares of common stock and 84 restricted stock units, each representing a contingent right to receive one share of Medpace common stock.
Medpace Holdings, Inc. director Robert O. Kraft exercised 33 restricted stock units into 33 shares of common stock on March 31, 2026. This reflects the first vesting installment from a November 28, 2025 grant of 130 restricted stock units scheduled to vest quarterly through December 31, 2026. Following the transaction, he holds 922 shares of common stock directly and 97 restricted stock units representing an equal number of potential future shares.
Medpace Holdings director Brian T. Carley exercised restricted stock units into common stock. On March 31, 2026, 36 restricted stock units converted into 36 shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 32,789 shares and leaving 107 restricted stock units outstanding from a prior grant.
Medpace Holdings, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, executive pay advisory votes and several governance changes. The meeting will be held online on May 15, 2026 via www.virtualshareholdermeeting.com/MEDP2026.
Stockholders of record on March 19, 2026, when 28,558,039 common shares were outstanding, may vote. The Board recommends voting for all five director nominees, for ratifying Deloitte & Touche LLP as auditor, for the Say‑on‑Pay resolution, for holding Say‑on‑Pay annually, for removing supermajority voting and for allowing stockholders to call special meetings, and against a similar overlapping stockholder proposal.
The proxy also reviews 2025 performance, including revenue of $2,530.2 million, GAAP net income of $451.1 million, diluted EPS of $15.28 and EBITDA of $557.7 million, all up from 2024, and explains how these results influenced executive compensation decisions.
The Vanguard Group filed an Amendment No. 7 to its Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Medpace Holdings Inc. common stock following an internal realignment described in the filing.
The amendment explains certain Vanguard subsidiaries and business divisions will report ownership separately under SEC Release No. 34-39538; the filing is signed by Ashley Grim on 03/27/2026.
Medpace Holdings, Inc. executive vice president of operations Susan E. Burwig exercised employee stock options for 12,000 shares of common stock at an exercise price of $166.73 per share on March 18, 2026. The option had fully vested on October 27, 2025. Following the transactions, she owns 70,484 shares of common stock and 11,028 derivative securities directly.
Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and sold the resulting shares. He exercised options for 31,707 shares of common stock at an exercise price of $138.87 per share, then sold 31,707 shares in an open-market transaction at a weighted average price of $455.30 per share. Following these transactions, he holds 15,000 shares of Medpace common stock directly. The filing notes that the option vested in full on February 15, 2026 and that the sale price reflects multiple trades between $451.36 and $460.288 per share.